Lightspeed ultra 16 discovery ct 750 hd

The latest American Association of Physicists in Medicine Task Group 43 formalism and Variseed version 7.1 (Varian Medical Systems, Palo Alto, CA, USA) were used for treatment planning and post-implant dosimetry. One month after LDR-BT, post-implant dosimetry was performed using computed tomography (CT) and magnetic resonance imaging (MRI). CT was performed using a CT scanner (LightSpeed Ultra 16/Discovery CT 750HD; GE Healthcare, Milwaukee, WI, USA) with a 16 or 64 detector array. MRI was performed using a 5-channel SENSE cardiac coil with easy breathing, a slice thickness of 3 mm, and no cross-gap (Intera Achieva 1.5 T/Intera Achieva Nova Dual 1.5 T Pulsar; Philips Medical Systems, Eindhoven, The Netherlands). The following dose parameters were used and analyzed in this study: the minimum dose received by 90% of the prostate gland (D90), percentage of the target volume receiving a minimum of 100% of the prescribed dose (V100), minimum dose received by 30% of the urethral volume (UD30), rectal volume receiving 100% of the prescribed dose (RV100), and rectal volume receiving 150% of the prescribed dose (RV150).

Treatment design and post-implant dosimetric evaluation were carried out in accordance with the latest American Medical Association Task Group 43 protocols and Variseed version 7.1 (Varian Medical Systems, Palo Alto, CA, USA). For post-implantation dose measurements, computed tomography (CT) and magnetic resonance imaging (MRI) were carried out 1 month from LDR-BT. A CT with a 16- or 64-detector array CT scanner (LightSpeed Ultra 16/Discovery CT 750 HD; GE Healthcare, Milwaukee, WI, USA) was used [21 (link)]. Also, an MRI using a 5-channel SENSE cardiac coil was performed in easy-breathing conditions using a slice thickness of 3 mm and no cross-gap (Intera Achieva 1.5 T/Intra Achieva Nova Dual 1.5 T Pulsar: Philips Medical Systems, Philips Medical Systems, Eindhoven, The Netherlands) [21 (link)]. In this study, the following dosimetric parameters were evaluated: the minimum percentage of the prostate gland received at 90% (D90), the percentage of the PV receiving 100% of the specified minimum peripheral dose (V100), the percentage of the rectal volume receiving 100% of the specified dose (RV100), and the biologically effective dose (BED).

Treatment planning and post-implant dosimetry were performed using the latest American Association of Physicians in Medicine Task Group 43 formalism and Variseed version 7.1 (Varian Medical Systems, Palo Alto, CA, USA). A post-implant dosimetric study using computed tomography (CT) and magnetic resonance imaging (MRI) was performed 1 month after LDR-BT. CT was performed using a CT scanner with a 16 or 64 detector array (LightSpeed Ultra 16/Discovery CT 750 HD; GE Healthcare, Milwaukee, WI, USA), and MRI under respiratory depression was performed using a five-channel SENSE cardiac coil with a slice thickness of 3 mm and no cross-gap (Intera Achieva 1.5 T/Intra Achieva Nova Dual 1.5 T Pulsar; Philips Medical Systems, Eindhoven, The Netherlands). The dosimetric parameters analyzed in this study were the biological effective dose (BED), minimum dose received by 90% of the target volume (D90), percentage of target volume receiving at least 100% of the prescribed dose (V100), minimum dose received by 30% of the urethral volume (UD30), and rectal volume receiving 100% of the prescribed dose (RV100).